Health Condition 1: F20- Schizophrenia
Conditions
Interventions
Intervention1: adjunctive PUFA supplementation: fish oil capsule BD orally (1100mg EPA+1316mg DHA) for 6 weeks in patients of schizophrenia along with antipsychotic medications.
Control Intervention1:
Sponsors
central institute of psychiatry
Eligibility
Inclusion criteria
Inclusion criteria: Inclusion Criteria for Group 1 (supplement) 1.Inpatients satisfying the ICD 10-DCR [1993] criteria for schizophrenia. 2.Current positive symptoms rated �4 (moderate) on one or more of these BPRS items: conceptual disorganization, grandiosity, hallucinatory behaviour, unusual thought content. 3.In an early phase of illness as defined by having taken antipsychotic medications for a cumulative lifetime period of 2 years or less. 4.Age 18 -50 years of both the sexes. 5.Having at least primary level of education. 6.Those who give informed consent for participating in the study. Inclusion Criteria for Group 2 (placebo) 1.Inpatients satisfying the ICD 10-DCR [1993] criteria for schizophrenia 2.Age group of 18-50 years of both sexes. 3.In an early phase of illness as defined by having taken antipsychotic medications for a cumulative lifetime period of 2 years or less. 4.Having at least primary level of education. 5.Those who give informed consent for participating in the study.
Exclusion criteria
Exclusion criteria: Exclusion Criteria for Group 1 (supplement) 1.Any other major co-morbid psychiatric diagnosis and substance dependence excluding nicotine & caffeine. 2.Pregnancy. 3.BMI > 30 kg/m2 4.Not willing to give written informed consent. 5.Any current systemic dyslipidaemia characterised by total cholesterol level �240 mg/dL, triglyceride level �150 mg/dL, low-density lipoprotein cholesterol level �140 mg/dL, high-density lipoprotein cholesterol level Exclusion Criteria for Group 2 (placebo) 1.Any other major co-morbid psychiatric diagnosis and substance dependence excluding nicotine & caffeine. 2.Pregnancy. 3.BMI > 30 kg/m 2 4.Not willing to give written informed consent. 5.Any current systemic dyslipidaemia characterised by total cholesterol level �240 mg/dL, triglyceride level �150 mg/dL, low-density lipoprotein cholesterol level �140 mg/dL, high-density lipoprotein cholesterol level
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| cognitive functions acessed by CANTABTimepoint: baseline, 6 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| lipid profileTimepoint: baseline, 6 weeks | — |
Countries
India
Contacts
Public ContactROSHAN V KHANANDE
central institute of psychiatry
Outcome results
None listed